Scinai Immunotherapeutics (SCNI) Notes Payables (2021 - 2022)
Scinai Immunotherapeutics' (SCNI) quarterly Notes Payables came in at $382000.0 in Q4 2022, up 1.87% year-over-year from $375000.0 in Q4 2021, and up 1.87% quarter-over-quarter from $375000.0 in Q4 2021.
Powered by 
Analysis
Scinai Immunotherapeutics (SCNI) Notes Payables (2021 - 2022) Analysis & Trends
Scinai Immunotherapeutics has disclosed Notes Payables across 2 years of filings, most recently posting $382000.0 for Q4 2022.
- In Q4 2022, Notes Payables rose 1.87% year-over-year to $382000.0; the TTM figure through Dec 2022 stood at $382000.0 (up 1.87% YoY), while the FY2022 annual figure was $382000.0, up 1.87% from the prior year.
- Notes Payables came in at $382000.0 for Q4 2022 at Scinai Immunotherapeutics, up from $375000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $382000.0 in Q4 2022 to a low of $375000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Scinai Immunotherapeutics | 1.52 Bn | 1.52 Bn | -1.25 Mn |